CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?
Cronos Group stock climbs 17% in three months on strong revenue growth and margin gains, but rising competition and regulatory risks raise questions about its upside.
Zacks
CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?
Cronos Group stock climbs 17% in three months on strong revenue growth and margin gains, but rising competition and regulatory risks raise questions about its upside.
Zacks
More News
Transcript: Cronos Group Q2 2026 Earnings Conference Call
Cronos Group (TSX:CRON) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
Benzinga APIs provide real-time access to earnings call transcripts andread more...
Benzinga
HOOD Stock Gains After Price Target Hike Driven By Rothera’s Prediction Market Success
Robinhood is also adding crypto.com's OG event contracts to its app and buying minority stakes in the exchange and its prediction markets business, according to the Wall Street Journal.
Stocktwits
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Zacks
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Zacks
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Cronos (CRON) delivered earnings and revenue surprises of +200.00% and +24.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TLRY Plans Strategic Medical Cannabis Expansion: Time to Buy or Sell?
Tilray expands its medical cannabis strategy with HelloMD, adding virtual patient access as investors weigh growth potential against ongoing profitability challenges.
Zacks
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
Cronos Group posts 40% Q1 revenue growth, gains share in Canada and expands abroad, but fierce cannabis competition keeps investors cautious.